Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/4/2009

acture of conformance batches at our proposed secondary source supplier of pegloticase API. The above increases in expense were partially offset by approximately $3.2 million of lower technology transfer costs from our proposed secondary source supplier of pegloticase API as the majority of the work was performed in the prior year and has now been substantially completed. Additionally, we incurred lower expenses for reservation fees as the prior year period reflects a $2.2 million payment to BTG to reserve manufacturing space in their facility.

Selling, general and administrative expenses for the first nine months of 2009 were $25.4 million, compared with $27.3 million for the same period of 2008, a decrease of $1.9 million, or 7%. The decrease was primarily due to lower legal fees of $3.2 million as the prior year results reflect expenses for Oxandrin-related patent infringement litigation and $2.1 million of lower compensation and benefits, including share-based compensation, due primarily to decreased headcount and share-based awards. Partially offsetting the lower costs are $1.2 million in higher severance expenses, increased pre-launch market research and recruiting expenses of $1.1 million and $1.0 million, respectively, both incurred in preparation for a potential commercial launch of KRYSTEXXA.

Investment income, net for the first nine months of 2009 was $0.3 million, compared with $1.7 million for the same period of 2008, a decrease of $1.4 million, or 84%. The lower investment income was primarily due to decreased dividend and interest income from lower cash, cash equivalent and investment balances and as a result of lower yields earned on those investments.

Other expense, net for the first nine months of 2009 was $24.4 million, compared with $0.5 million for the same period of 2008, an increase of $23.9 million primarily as a result of the non-cash net loss on the mark-to-market valuation adjustment to our warrant l
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... The Assistance Fund announces the addition of ... assistance for copay to individuals diagnosed with Melanoma. ... of the Melanoma Copay Assistance Program to our portfolio ... director. "With each additional program we are closer to ... no one is denied access to medications due to ...
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
(Date:5/22/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has announced ... Application Dossiers for Oversea Medical device registration and ... to their offering. The Chinese medical ... the most growth potentiality, which is attracting more ... to penetrate such market. It is estimated that ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... JERUSALEM, Jan. 11 IDenta Corp. (PinkSheets: IDTA) announced today ... a General Screening Explosive Identifier. , This kit has been ... ampoules it contains, the following substances can be identified with ... Identifier.. , Ampoule 1: TNT, DNT, Tetryl. , Ampoule ...
... LAGUNA BEACH, California, January 11 Advanced ... announced today that it has completed a $5 million ,Series,B, ... venture,capital firm specialized in medical technology investments, and is expected,to ... was founded in 2007 to develop a novel irrigated radiofrequency,cardiac ...
Cached Medicine Technology:International Drug & Explosives Detection Firm IDenta Corp Announces that the TNT/PETN/RDX/NITRATE Test Kit can be used as a General Screening Explosive Identifier 2International Drug & Explosives Detection Firm IDenta Corp Announces that the TNT/PETN/RDX/NITRATE Test Kit can be used as a General Screening Explosive Identifier 3Advanced Cardiac Therapeutics Completes $5 Million Financing 2Advanced Cardiac Therapeutics Completes $5 Million Financing 3
(Date:5/26/2015)... (PRWEB) May 26, 2015 Learning ZoneXpress ... line, Nutrition Education Cards . These cards have ... engaging photography and simple, easy-to-read text, these new educational ... . They offer practical nutrition tips and suggestions to ... titles available are: , + MyPlate: Eat for a ...
(Date:5/26/2015)... 2015 Writers and editors can ... Vasont® CCMS to make creating, editing, and managing ... component content management system (CCMS) software provider, certified ... oXygen XML Editor Version 17.0, Syncro Soft’s latest ... extension merges key editorial functionality of the Vasont ...
(Date:5/26/2015)... Ore. (PRWEB) May 26, 2015 ... association which provides talent development to credit union CEOs, ... for their employees to boost the bottom line. CUES ... program that has helped dozens of credit unions across ... According to a 2014-2015 Staff Benefits Report ...
(Date:5/26/2015)... DENVER (May 26, 2015) – As ... is also experiencing many of the growing pains felt ... one major issue that cannabis companies now have to ... paper and plastic that marijuana growers, dispensaries and consumers ... we see the opportunity to enhance our environment for ...
(Date:5/26/2015)... General Networks Corporation today announced ... alliance ensures joint customers will benefit from the ... expertise in building enterprise content and process management ... customers integrate, manage and operationalize their data and ... “Our customers are seeking tools to make better ...
Breaking Medicine News(10 mins):Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2Health News:CUES Expects a Positive Return on Wellness with hubbub health™ 2Health News:CUES Expects a Positive Return on Wellness with hubbub health™ 3Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 2Health News:Colorado Cannabis Business Expands its Recycling Initiative, to Encourage Marijuana Retailers to Keep Their Businesses Green 3Health News:General Networks Corporation Announces Alliance with MarkLogic 2
... patients who undergo chemotherapy or radiation expect a high number ... chemotherapy or radiation can diminish the quality of life for ... as nausea, he or she is more likely to develop ... and the type of cancer influence how many side effects ...
... Patients with rheumatoid arthritis who receive a more intensive ... remission of their disease, finds a new study.// ... patients with similar levels of disease to one of ... drugs to fight rheumatoid arthritis, along with steroid injections. ...
... people in every 100,000. It is most common in people ... Simple exercises performed at home may help patients with vertigo ... ,Researchers studied 70 patients who had a form of vertigo ... Participants reported experiencing episodes of nausea or a feeling of ...
... the Centers for Disease Control and Prevention says 30 percent ... percentile,// and 15 percent of children have a BMI above ... years and the National Institutes of Health report that overweight ... keeps them at high risk for heart disease, diabetes, high ...
... can be done to activate the cells to destroy tumors. ... // cancer may be due to different cell priming or ... found a method to activate the anti-cancer cells in mice. ... patients and separated the anti-cancer cells. The cells were stimulated ...
... A new study shows soy protein with isoflavones does ... mineral density, or cholesterol in postmenopausal women.// ... menopause is related to a decrease in bone mineral ... cholesterol. Some women have taken hormone therapy to offset ...
Cached Medicine News:
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
Qualcraft Radiation Readers, Carbon Glasses. Protect yourself and have close-vision clarity....
The Bronze Metalite Constructed of optical-grade steel with bronze electroplate. Fitted lead side shields that create a seal to the front of the lenses for increased scatter protection....
Medicine Products: